Changes in Salivary Asprosin, IL-39, IL-40 and IL-1β Levels in Diabetic Patients with Periodontitis
Launched by NECMETTIN ERBAKAN UNIVERSITY · Dec 11, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying certain substances in saliva called biomarkers—specifically asprosin, IL-39, IL-40, and IL-1β—to see how they relate to diabetes and gum disease, known as periodontitis. The researchers want to find out if these biomarkers differ between people with and without diabetes, and between those with periodontitis and those who have healthy gums. The goal is to see if these biomarkers can help diagnose gum disease early or track its progress over time.
To participate in this study, individuals must be between the ages of 18 and 65 and should not have certain health conditions like serious kidney or heart problems. They should also have at least 20 teeth and should not have received recent dental treatments or antibiotics. The study is currently not recruiting participants, but if someone is eligible, they can expect to provide saliva samples and undergo dental examinations to assess their gum health. This research could provide valuable insights into the connection between diabetes and gum disease, which is important for developing better care strategies.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria:- No systemic disease such as nephrotic syndrome, chronic renal disease and cardiovascular disease
- • No dental scaling and root planing treatment in the last 6 months
- • No antibiotic use for any reason
- • Having at least 20 teeth in the mouth
- • Not being pregnant or breastfeeding
- • Inclusion criteria for the periodontally healthy group
- • Having a periodontally healthy diagnosis in routine clinical and radiographic examinations Inclusion criteria for the periodontitis group
- • Diagnosing periodontitis in routine clinical and radiographic examinations
- Exclusion Criteria:
- • - Patients with any autoimmune disease (Rheumatoid arthritis, familial Mediterranean fever, ankylosing spondylitis, Behcet, psoriasis, etc.) - Those who smoke 10 or more cigarettes per day
About Necmettin Erbakan University
Necmettin Erbakan University is a prominent academic institution dedicated to advancing health sciences and research through innovative clinical trials. With a commitment to excellence in education and research, the university leverages its multidisciplinary approach to foster collaborations that enhance patient care and medical advancements. By conducting rigorous clinical studies, Necmettin Erbakan University seeks to contribute valuable insights to the medical community, ultimately improving treatment outcomes and fostering evidence-based practices in healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Konya, Meram, Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported